Adele Schulz

Global Customer Insight Director, Respiratory Franchise at GlaxoSmithKline plc

Location:
5 Crescent Drive, Philadelphia, Pennsylvania, United States
Company:
GlaxoSmithKline plc
HQ Phone:
(215) 751-4000
Wrong Adele Schulz?

Last Updated 1/1/2017

General Information

Employment History

Pharmaceutical Industry Analyst  - Datamonitor plc

Web References  

Pharmaceutical Field the magazine for medical sales professionals

Off-label use will continue to have a place in niche indications with high unmet need, or as a feasible strategy for second- and third-to-indication members of product classes experiencing off-label uptake in an indication. ,However,, Schulz says, ,companies must be aware that off-label promotion in commercially attractive populations will be subjected to increased scrutiny in future., Schulz says: ,Growing use of pharmacogenomics will contribute to this shift, as initiatives to streamline the drug development process using biomarkers to identify patient populations in which a treatment will have an enhanced risk-benefit profile grow in prominence., Adele Schulz, Datamonitor pharmaceutical industry analyst, is available for comment.Her Datamonitor report ,Lifecycle Management: Accessing New Patient Populations , Maximising Return on Investment of Indication Management, is a case study-based analysis targeting the creation of best practice recommendations for entering new patient populations in the US and Europe.

Read More
Hospitalpharma.com: The online resource for hospital pharmacy

Datamonitor's Adele Schulz offers pharmaceutical companies some practical solutions to help stop the financial bleeding ...

Read More
PharmaLive: DATAMONITOR: Will legislation squeeze life out of indication expansion?

Whereas patents filed for multiple indications had previously resulted in multiple 30-month delays of generic approval, MMA restricts each company to one 30-month stay, triggered when the originator companies sues a generics player for challenging any listed patent, Schulz says. However a number of high-profile drug safety issues (including the withdrawal of Vioxx in late-2004, and investigation of the links between selective serotonin reuptake inhibitor,s (SSRI) and suicide) are changing the environment for pharmaceuticals- and pharmaceutical marketing in particular- and may reduce the potential for companies to profit from off-label use of their products, Schulz says. In relation to this, Datamonitor expects to see an evolution of this lifecycle management strategy from one of indication ,expansion, to one of indication ,targeting, or ,selection,, which implies a more focused, product specific approach to implementation, Schulz says. ,Growing use of pharmacogenomics will contribute to this shift, as initiatives to streamline the drug development process using biomarkers to identify patient populations in which a treatment will have an enhanced risk-benefit profile grow in prominence., Although segmenting the patient population, Schulz says, indication targeting will result in numerous lifecycle benefits, including: Adele Schulz, Datamonitor pharmaceutical industry analyst and report author is available for comment

Read More

Browse ZoomInfo’s Directories